Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 6/2019

01-11-2019 | Breast Cancer | Original Article

Preoperative mean platelet volume predicts survival in breast cancer patients with type 2 diabetes

Authors: Na Li, Xin-hai Lv, Xin Wang, Rui-tao Wang, Yuan-xi Huang

Published in: Breast Cancer | Issue 6/2019

Login to get access

Abstract

Purpose

Patients with type 2 diabetes mellitus (T2DM) have an increased risk of breast cancer (BC). Furthermore, growing evidence suggests that activated platelets play a crucial role in tumor and T2DM. Mean platelet volume (MPV) is a platelet index and is altered in patients with malignancies. The aim of this study was to determine whether preoperative MPV could predict survival in BC patients with T2DM.

Methods

The clinical data of 266 female BC patients with T2DM and 264 female BC patients without T2DM between January 2011 and December 2011 in our center were retrospectively analyzed. Survival analysis was performed using the log-rank test and Cox proportional hazards regression analysis.

Results

The patients with T2DM had higher MPV levels than the patients without T2DM. Furthermore, MPV was found to be significantly associated with differentiation T2DM from non-T2DM. In addition, survival analysis revealed that the disease-specific survival and overall survival of patients with MPV ≤ 8.0 fL were significantly shorter than that of those with MPV > 8.0 fL in diabetic patients. Multivariate analysis identified MPV as an independent poor prognostic factor for survival only in patients with T2DM not in patients without T2DM.

Conclusions

Our study first established a connection between MPV and BC patients with T2DM, suggesting that MPV was an independent prognostic factor and could be the biomarker for prognosis.
Literature
1.
DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.CrossRefPubMed
2.
Zhao XB, Ren GS. Diabetes mellitus and prognosis in women with breast cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2016;95(49):e5602.CrossRef
3.
Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol. 2011;29(1):40–6.CrossRefPubMed
4.
Mezouar S, Frere C, Darbousset R, et al. Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences. Thromb Res. 2016;139:65–766.CrossRefPubMed
5.
Suzuki K, Aiura K, Kitagou M, et al. Platelets counts closely correlate with the disease-free survival interval of pancreatic cancer patients. Hepatogastroenterology. 2004;51(57):847–53.PubMed
6.
Long Y, Wang T, Gao Q, Zhou C. Prognostic significance of pretreatment elevated platelet count in patients with colorectal cancer: a meta-analysis. Oncotarget. 2016;7:81849.PubMedPubMedCentral
7.
Pietrzyk L, Plewa Z, Denisow-Pietrzyk M, Zebrowski R, Torres K. Diagnostic power of blood parameters as screening markers in gastric cancer patients. Asian Pac J Cancer Prev. 2016;17(9):4433–7.PubMed
8.
Ekici H, Malatyalioglu E, Kokcu A, Kurtoglu E, Tosun M, Celik H. Do Leukocyte and platelet counts have benefit for preoperative evaluation of endometrial cancer. Asian Pac J Cancer Prev. 2015;16(13):5305–10.CrossRefPubMed
9.
Qiu J, Yu Y, Fu Y, Ye F, Xie X, Lu W. Preoperative plasma fibrinogen, platelet count and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res. 2012;38(4):651–7.CrossRefPubMed
10.
Seretis C, Youssef H, Chapman M. Hypercoagulation in colorectal cancer: what can platelet indices tell us. Platelets. 2015;26(2):114–8.CrossRefPubMed
11.
Gasparyan AY, Ayvazyan L, Mikhailidis DP, et al. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17(1):47–58.CrossRefPubMed
12.
13.
14.
15.
Tanriverdi O, Menekse S, Teker F, et al. The mean platelet volume may predict the development of isolated bone metastases in patients with breast cancer: a retrospective study of the Young Researchers Committee of the Turkish Oncology Group (TOG). J BUON. 2016;21(4):840–50.PubMed
16.
Kodiatte TA, Manikyam UK, Rao SB, Jagadish TM, Reddy M, Lingaiah HK, Lakshmaiah V. Mean platelet volume in Type 2 diabetes mellitus. J Lab Physicians. 2012;4:5–9.CrossRefPubMedPubMedCentral
17.
Tesfamariam B. Involvement of platelets in tumor cell metastasis. Pharmacol Ther. 2016;157:112–9.CrossRefPubMed
18.
Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 2005;7(5):R788–R795795.CrossRefPubMedPubMedCentral
19.
Kang DW, Min DS. Platelet derived growth factor increases phospholipase D1 but not phospholipase D2 expression via NFkappaB signaling pathway and enhances invasion of breast cancer cells. Cancer Lett. 2010;294(1):125–33.CrossRefPubMed
20.
Boucharaba A, Serre CM, Grès S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 2004;114(12):1714–25.CrossRefPubMedPubMedCentral
21.
Appiah-Kubi K, Wang Y, Qian H, et al. Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers. Tumour Biol. 2016;37(8):10053–66.CrossRefPubMed
22.
Lian L, Li W, Li ZY, et al. Inhibition of MCF-7 breast cancer cell-induced platelet aggregation using a combination of antiplatelet drugs. Oncol Lett. 2013;5(2):675–80.CrossRefPubMed
23.
Aksoy S, Kilickap S, Hayran M, et al. Platelet size has diagnostic predictive value for bone marrow metastasis in patients with solid tumors. Int J Lab Hematol. 2008;30(3):214–9.CrossRefPubMed
24.
Wang X, Cui MM, Xu Y, et al. Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer. Oncotarget. 2017;8:68115.PubMedPubMedCentral
25.
26.
Gu M, Zhai Z, Huang L, et al. Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer. Breast Cancer. 2016;23(5):752–60.CrossRefPubMed
27.
Dindar S, Cinemre H, Sengul E, Annakkaya AN. Mean platelet volume is associated with glycaemic control and retinopathy in patients with type 2 diabetes mellitus. West Indian Med J. 2013;62(6):519–23.CrossRefPubMed
28.
Han JY, Choi DH, Choi SW, et al. Stroke or coronary artery disease prediction from mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2013;24(5):401–6.CrossRefPubMed
29.
Mu L, Zhu N, Zhang J, Xing F, Li D, Wang X. Type 2 diabetes, insulin treatment and prognosis of breast cancer. Diabetes Metab Res Rev. 2017;33(1):2823.CrossRef
30.
Ferroni P, Riondino S, Buonomo O, Palmirotta R, Guadagni F, Roselli M. Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress. Oxid Med Cell Longev. 2015;2015:183928.CrossRefPubMedPubMedCentral
31.
Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63:1721–7.CrossRefPubMed
Metadata
Title
Preoperative mean platelet volume predicts survival in breast cancer patients with type 2 diabetes
Authors
Na Li
Xin-hai Lv
Xin Wang
Rui-tao Wang
Yuan-xi Huang
Publication date
01-11-2019
Publisher
Springer Japan
Published in
Breast Cancer / Issue 6/2019
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-019-00976-1

Other articles of this Issue 6/2019

Breast Cancer 6/2019 Go to the issue

Original Article

Transgelin-2 expression in breast cancer and its relationships with clinicopathological features and patient outcome

Original Article

Pharmacotherapy decision-making among patients with breast cancer in Japan: results of an online survey

Original Article

Comparison of central sensitization-related symptoms and health-related quality of life between breast cancer survivors with and without chronic pain and healthy controls

Original Article

Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis

Acknowledgment

Acknowledgements to reviewers 2019

Original Article

Icariin induces apoptosis by suppressing autophagy in tamoxifen-resistant breast cancer cell line MCF-7/TAM
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits